PCYN (Procyon) Beta: 120486.3482 (As of Jun. 24, 2026)


PCYN Procyon Corp PCYN
48 GF Score
Price $0.20
View Full Analysis

What is Procyon Beta?

Procyon PCYN 48 Beta is 120486.3482 as of Jun. 24, 2026. GuruFocus rates PCYN with a GF Score™ of 48/100.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Procyon's Beta is 120486.3482.


Procyon  (OTCPK:PCYN) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Procyon Beta Related Terms


Procyon Beta Historical Data

* Premium members only.

The historical data trend for Procyon's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Procyon Beta Chart

Procyon Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.12 -0.19 -0.73 -1.24

Procyon Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.73 -0.73 -1.30 -1.22 -1.24

PCYN vs KAYS, YCBD, CBDY: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Procyon's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Procyon Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procyon's Beta distribution charts can be found below:

* The bar in red indicates where Procyon's Beta falls into.


PCYN
48GF Score
Procyon Corp PCYN
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Procyon Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 120486.3482 mean?
Procyon (PCYN) has a Beta of 120486.3482 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Procyon and its competitors.
Is Procyon's Beta too high?
Procyon's current Beta is 120486.3482. Overall, Procyon has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Procyon's Beta compare to KAYS and YCBD?
Procyon's Beta of 120486.3482 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Procyon and its competitors. Procyon's current Beta is 120486.3482. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procyon stock overvalued right now?
Procyon (PCYN) has a current Beta of 120486.3482. The current Beta is 120486.3482. Procyon's overall GF Score™ is 48/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Procyon (PCYN), the current Beta is 120486.3482 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Procyon Business Description

Address 164 Douglas Road East, Oldsmar, FL, USA, 34677
Procyon Corp is a United-based company, through its subsidiary, it is engaged in developing and marketing proprietary medical products used to treat pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems. Its wound care products are sold through distributors to institutional customers such as hospitals, wound care clinics, skilled nursing facilities, home health agencies, and physicians and other healthcare practitioners. The firm's product lines are AMERX, AMERIGEL, and HELIX3 Bioactive Collagen. The skin and wound care products are marketed under the trademark AMERIGEL which contains the proprietary ingredient OAKIN which promotes wound healing and healthy skin. The corporation markets its products in the United States.
48GF Score

Get the complete analysis for PCYN

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20
Price